Semaglutide vs Tirzepatide — Liver Health Comparison

Patients and clinicians often conflate brand names with active ingredients. For liver disease prescribing, the distinction matters:

All liver-specific phase 3 evidence for semaglutide uses the 2.4mg dose (Wegovy). Ozempic at 1mg produces lower-magnitude but clinically meaningful hepatic benefit through weight loss and glycaemic improvement. Tirzepatide liver data spans multiple dose levels in phase 2, with phase 3 SYNERGY-NASH using the 15mg maintenance dose.

Semaglutide is a selective GLP-1 receptor agonist with 94% homology to native GLP-1. It activates GLP-1 receptors in pancreatic beta cells, hypothalamus, gastrointestinal tract, and hepatic tissue. Hepatic effects include reduced de novo lipogenesis, improved insulin signalling, and indirect reduction of hepatic steatosis through weight loss.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. GIP receptor activation adds complementary metabolic effects: enhanced insulin secretion, adipose tissue modulation, and potentially direct hepatic lipogenesis suppression. Both GLP-1 and GIP receptors are expressed in liver tissue, suggesting additive hepatic pathways beyond weight loss alone.

The dual mechanism explains tirzepatide's superior average weight loss in SURMOUNT-5 (approximately 20% vs 14% for semaglutide at 72 weeks). Since weight loss magnitude is the primary driver of liver fat reduction in MASLD, this difference has direct clinical relevance for hepatic outcomes.

The ESSENCE trial (NEJM, May 2025) is the landmark phase 3 study for semaglutide in MASH. Key results at 72 weeks with semaglutide 2.4mg:

• MASH resolution without worsening of fibrosis: 62.9% vs 34.3% placebo
• Fibrosis improvement by ≥1 stage: 36.8% vs 22.4% placebo
• Mean body weight reduction: approximately 13%
• Liver enzyme normalisation in a significant proportion of participants

Based on ESSENCE data, the TGA provisionally approved Wegovy (semaglutide 2.4mg) in April 2026 for adults with non-cirrhotic MASH with moderate to advanced liver fibrosis (Metavir F2–F3). This is the first GLP-1 receptor agonist with formal regulatory approval for liver disease in Australia.

Real-world data on Ozempic 1mg consistently demonstrates ALT/AST improvement and liver fat reduction in MASLD patients with type 2 diabetes, at lower magnitude than the Wegovy dose used in ESSENCE.

Tirzepatide phase 2 dedicated liver disease trials demonstrated significant reductions in liver fat content (measured by MRI-PDFF), ALT/AST normalisation, and histological improvement in MASH subsets. Over 62% of participants with inflammatory MASH saw resolution in a dedicated 52-week trial.

SYNERGY-NASH is the definitive phase 3 trial — randomised, double-blind, placebo-controlled, with liver biopsy endpoints (MASH resolution and fibrosis improvement). Enrolment completed in 2025; results expected in 2026. This trial will provide the histological comparison needed for a potential TGA MASH indication for tirzepatide.

Until SYNERGY-NASH results are published, tirzepatide cannot be prescribed under a TGA-approved MASH indication. Off-label use for MASLD with metabolic comorbidities is clinically reasonable given weight loss data and phase 2 hepatic outcomes, but lacks the regulatory framework that now exists for semaglutide.

SURMOUNT-5 (NEJM, May 2025) provides the only direct head-to-head comparison: tirzepatide 15mg vs semaglutide 2.4mg in patients with obesity without diabetes. Tirzepatide achieved approximately 20.2% mean weight loss vs 14.9% for semaglutide at 72 weeks.

For liver disease management, this 5–6 percentage point difference in weight loss is clinically meaningful. MASLD research establishes that:

• ≥7% weight loss produces significant liver fat reduction
• ≥10% weight loss is associated with MASH resolution in many patients
• ≥15% weight loss may produce fibrosis regression in selected patients

On weight loss grounds alone, tirzepatide would be expected to produce superior hepatic steatosis reduction. However, ESSENCE demonstrates that semaglutide 2.4mg achieves MASH resolution independent of weight loss magnitude in a substantial proportion of patients — suggesting direct hepatic GLP-1 effects beyond weight loss.

Patient-facing Ozempic vs Mounjaro comparison →

For patients with biopsy-confirmed MASH at F2–F3 fibrosis requiring TGA-approved pharmacotherapy, semaglutide 2.4mg (Wegovy) is currently the only option. Tirzepatide may become an alternative following SYNERGY-NASH publication and TGA review.

The MJA September 2025 consensus statement and AASLD November 2025 guidance recommend identical baseline and follow-up assessment regardless of which incretin therapy is prescribed:

1. Baseline FIB-4 from routine bloods (ALT, AST, platelets, age)
2. Transient elastography for FIB-4 indeterminate (1.3–2.67) or high-risk patients
3. Document baseline liver stiffness (kPa) and CAP/UAP fat score
4. Annual LFTs and repeat elastography at 12 months during treatment
5. Specialist referral if liver stiffness ≥8 kPa or FIB-4 >2.67

Treatment response assessment should include both biochemical markers (ALT/AST normalisation) and elastography (liver stiffness and fat score reduction). Histological reassessment via biopsy is reserved for clinical trial contexts or cases where non-invasive results are discordant with clinical progression.

FibroScan availability in Australia →

Find an elastography clinic →

Choose semaglutide 2.4mg (Wegovy) when: MASH F2–F3 confirmed on biopsy or validated non-invasive staging; TGA-approved indication required; patient needs the most evidence-supported MASH pharmacotherapy available now.

Choose semaglutide 1mg (Ozempic) when: Type 2 diabetes with MASLD; PBS subsidy required; MASH not yet confirmed — weight loss and glycaemic control drive hepatic benefit.

Choose tirzepatide when: Maximum weight loss needed for MASLD management; semaglutide inadequate at tolerated doses; MASH not yet at treatment threshold; awaiting SYNERGY-NASH data before MASH-specific indication decision.

Both medications carry class warnings for gallstone risk (approximately 27% increased vs non-GLP-1 users). Rapid weight loss monitoring and patient education on biliary symptoms are recommended for both.

GLP-1 gallstone risk — clinical guide →